p53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin

Melanoma Research

Volumn 14, Issue 5, 2004, Pages 395-401

  Ragnarsson Olding, Boel ^a,b   Platz, Anton ^b   Olding, Lars ^b   Ringborg, Ulrik ^a,b  

^a Department of Oncology ^*  (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cutaneous melanoma; Extracutaneous melanoma; Mucosal melanoma; p53p

Indexed keywords

PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MUCOSA; PRIORITY JOURNAL; SKIN TUMOR; STATISTICAL SIGNIFICANCE; SUN EXPOSURE; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUCOUS MEMBRANE; MUTATION; SKIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 7244225177     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200410000-00010     Document Type: Article

References (49)

1. The Swedish National Cancer Registry. Cancer incidence in Sweden 1960-1999. Stockholm: National Board of Health and Welfare, Centre for Epidemiology.
2. Ragnarsson-Olding B. Malignant melanoma of the vulva [Doctoral Thesis]. Stockholm: Karolinska Institute; 1999. Free copy on request.
3. Ragnarsson-Olding B, Johansson H, Rutqvist LE, Ringborg U. Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer 1993; 71:1893-1897.
4. Ragnarsson-Olding B, Larson B, Ringborg U. Malignant melanoma of the vulva. CME J Gynecol Oncol 1997; 2:298-305.
5. Ragnarsson-Olding BK, Kanter-Lewensohn LR, Lagerlöf B, Nilsson BR, Ringborg UK. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathological features. Cancer 1999; 86:1273-1284.
6. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, Lagerlöf B, Ringborg UK. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999; 86:1285-1293.
7. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998; 111:757-761.
8. Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 2002; 12:453-463.
9. van der Lubbe J, Rosdorff H, Bos J, van der Eb A. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res 1988; 3:9-20.
10. Pierceall WE, Kripke ML, Ananthaswamy HN. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res 1992; 52:3946-3950.
11. Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994; 102:819-821.
12. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DN, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4:35-45.
13. Akslen LA, Monstad SE, Larsen B, Straume O. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79:91-95.
14. Zerp SF, van Elsas A, Peltenburg L, Schrier PI. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanoma genesis. Br J Cancer 1999; 79:921-926.
15. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sun-light in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88:10 124-10 128.
16. Dumaz N, van Kranen HJ, de Vries A, Berg RJW, Wester PW, van Kreijl CF, et al. The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 1997; 18:897-904.
17. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Invest Dermatol Symp Proc 1996; 1:136-142.
18. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90:4216-4220.
19. Flørenes VA, Øyjord T, Holm R, Skrede M, Børresen A-L, Nesland JM, et al. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 1994; 69:253-259.
20. Sparrow LE, Soong R, Dawkins HJS, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995; 5:93-100.
21. MacGeoch C, Barnes DM, Newton JA, Mohammed S, Hodgson SV, Ng M, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11:239-250.
22. Rauth S, Kichina J, Green A, Bratescu L, Das Gupta TK. Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice. Anticancer Res 1994; 14:2457-2463.
23. Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhom-Dworniczak B. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 1995; 7:331-339.
24. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87:7555-7559.
25. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7:743-749.
26. Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofolini P, Dalla Palma P, et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993; 129:739-743.
27. van Dijk M, Sprenger S, Rombout P, Marres H, Kaanders J, Jeuken J et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative hybridization. Genes, Chromosomes Cancer 2003; 36:151-158.
28. Ouhtit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, Yamasaki H, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst 1998; 90:523-531.
29. Taylor JA, Li Y, He M, Mason T, Mettlin C, Vogler WJ, et al. p53 mutations in bladder tumors from arylamine-exposed workers. Cancer Res 1996; 55:294-298.
30. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994; 54:231-235.
31. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995; 55:2665-2672.
32. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278:261-263.
33. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136.
34. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992; 11:5013-5020.
35. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357:82-85.
36. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58 kD tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kD cellular protein in transformed cells. Cell 1982; 28:387-394.
37. Maxwell SA, Ja R. Posttranslational regulation of p53 tumor suppressor protein function. Crit Rev Oncog 1994; 5:23-57.
38. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002; 8:3468-3474.
39. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000.
40. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-6488.
41. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 63:3955-3957.
42. Platz A, Ringborg U, Hansson J. Hereditary cutaneous melanoma. Semin Cancer Biol 2000; 10:319-326.
43. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003; 95:790-798.
44. van Elsas A, Zerp SF, van der Flier S, Krüse KM, Aamoudse C, Hayward NK, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149:883-893.
45. Kumar R, Smeds J, Lundh Rozell B, Hemminki K. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas. Melanoma Res 1999; 9:138-147.
46. Wagner SN, Wagner C, Briedigkeit L, Goos M. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 1998; 138:13-21.
47. Flores J. Loss of the p16INK4a and p15INK4b genes as well as neighbouring 9p21 markers in sporadic melanoma. Cancer Res 1996; 56:5023-5032.
48. Tran TP, Titus-Ernstoff L, Perry AE, Ernstoff MS, Newsham IF. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control 2002; 13:675-682.
49. Hussein M, Haemel A, Wood G. p53-related pathways and the molecular pathogenesis of melanoma. Eur J Cancer Prev 2003; 12:93-100.